The European BRCA patent oppositions and appeals: coloring inside the lines

The patents on BRCA1 and BRCA2 held by Myriad Genetics have been the subject of much attention in the United States recently, but the fire was lit in Europe more than a decade ago.

Saved in:
Bibliographic Details
Published inNature biotechnology Vol. 31; no. 8; pp. 704 - 710
Main Authors Matthijs, Gert, Huys, Isabelle, Van Overwalle, Geertrui, Stoppa-Lyonnet, Dominique
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.08.2013
Nature Publishing Group
Subjects
631/208/2489/1512
706/648/270
Agriculture
Bioinformatics
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
BRCA1 Protein - genetics
BRCA2 Protein - genetics
Breast cancer
Breast Neoplasms - epidemiology
Breast Neoplasms - genetics
Europe
Female
Genetics
Humans
Life Sciences
Ovarian Neoplasms - epidemiology
Ovarian Neoplasms - genetics
Patients
Europe
United States > US
Online AccessGet full text

Cover

More Information
Summary:The patents on BRCA1 and BRCA2 held by Myriad Genetics have been the subject of much attention in the United States recently, but the fire was lit in Europe more than a decade ago.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1087-0156
1546-1696
1546-1696
DOI:10.1038/nbt.2644